All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The AML Global Portal were delighted to speak to John DiPersio, Washington University Medical School, St. Louis, US, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked John DiPersio: Is AML susceptible to immunotherapy? He outlined the current challenges of immunotherapeutic approaches in AML, such as lack of selective targets and life-threatening side-effects, and how they can potentially be overcome.
Is AML susceptible to immunotherapy?
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox